MedTrace Logo

DHA Supplementation in Patients With STGD3

NCT00420602 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-05-09

No results posted yet for this study

Summary

We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Conditions

  • Dominantly Inherited Stargardt's Disease (STGD3)

Interventions

DIETARY_SUPPLEMENT

Over the counter DHA/EPA dietary supplementation

1000 mg/day DHA/EPA

Sponsors & Collaborators

Principal Investigators

  • Paul S. Bernstein, MD Ph.D. · University of Utah

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-21
Primary Completion
2017-12-27
Completion
2017-12-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420602 on ClinicalTrials.gov